PDS Biotech’s oncology pipeline leverages the Versamune® and Versamune® plus PDS0301 platform technologies in combination with proprietary tumor-specific proteins or peptides (antigens) in the development of targeted cancer immunotherapies. 


This website use cookies to facilitate the use of the website, improve its performance and security, personalize the proposed content.